Urinary proteomics identifies distinct immunological profiles of sepsis associated AKI sub-phenotypes
2024

Urinary Proteomics and Sepsis-Associated Acute Kidney Injury

Sample size: 173 publication 10 minutes Evidence: high

Author Information

Author(s): Stanaway Ian B., Morrell Eric D., Mabrey F. Linzee, Sathe Neha A., Bailey Zoie, Speckmaier Sarah, Lo Jordan, Zelnick Leila R., Himmelfarb Jonathan, Mikacenic Carmen, Evans Laura, Wurfel Mark M.

Primary Institution: University of Washington

Hypothesis

The study aims to understand the underlying biology that differentiates acute kidney injury (AKI) sub-phenotypes and their associations with kidney outcomes.

Conclusion

The study identifies distinct immunological profiles between AKI sub-phenotypes, suggesting potential therapeutic targets and the utility of urine proteomics for non-invasive classification.

Supporting Evidence

  • 117 urine proteins were higher in AKI-SP2, while 195 were higher in AKI-SP1.
  • Pathways related to immune response were upregulated in AKI-SP2.
  • Patients with AKI-SP2 had a higher risk of renal replacement therapy compared to AKI-SP1.

Takeaway

Doctors can tell different types of kidney problems in sick patients by looking at their urine, which helps them decide how to treat them better.

Methodology

The study enrolled 173 ICU patients with sepsis, classified them into AKI sub-phenotypes using plasma biomarkers, and analyzed urinary proteins using aptamer-based proteomics.

Potential Biases

Aptamer-based methods may be affected by probe cross-reactivity and nonspecific binding.

Limitations

The AKI-SP2 population is small, and urine output data was missing for some patients, which may affect the findings.

Participant Demographics

Mean age was 53 years, 61% were men, and the racial breakdown included 57% White, 17% Black, 12% Asian, and 21% LatinX.

Statistical Information

P-Value

p=0.007

Confidence Interval

95% CI: 0.69–0.99

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/s13054-024-05202-9

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication